Hep C showdowns; M&A mania;

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

> Slimdown craze still on, with sales and spinoffs galore. Slim fast? Not necessarily. More

> Will biopharma keep riding that mammoth M&A wave? Short answer's yes. More

> Limited attention span? Focus on these market shake-ups in 2015. More

> Get ready to negotiate, drugmakers: Payers are armed for drug-pricing battle. More

> Continuous manufacturing reaches a turning point. More

Subscribe to FiercePharma >>

The 5 top trends for med tech in 2014

> Merger mania remakes the landscape. More

> Med tech tackles tough problems. More

> The rapid consumerization of med tech. More

> Google goes after med tech, along with other VCs. More

> Reimbursement continues to be a challenge. More

Subscribe to FierceMedicalDevices >>

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.